4/20/2007 | SS | Shire completes acquisition of New River
|
4/18/2007 | SS | Shire completes tender offer for New River shares
|
4/16/2007 | SS | Shire shareholders vote to approve New River tender offer, increase borrowings
|
4/3/2007 | CV | New River says 3.5% notes will be convertible through June 30
|
3/29/2007 | SS | Gabelli, Gamco report 5.39% combined stake in New River Pharmaceuticals
|
2/20/2007 | SS | Market Commentary: XM, Sirius up; EMI, Warner up; Vulcan lifts Rinker; Shire, New River rise; Tessco up, Sirva up
|
2/20/2007 | SS | Shire to acquire New River Pharmaceuticals for $64 per share
|
11/27/2006 | SS | Ford shares, preferreds skid; Nasdaq, LSE slip; biotechs lower; Raytheon drops; Ventas falls
|
11/9/2006 | BT | New River reiterated at buy by Merrill
|
10/10/2006 | BT | Merrill puts New River at buy, raises price target
|
10/9/2006 | BT | Market Commentary: New River rises 61.5%, Shire up 16% on ADHD drug nod; Coley eyed; NeoPharm higher by 20%
|
10/9/2006 | CV | Market Commentary: Amkor splits ways with defaults cured; New River quiet despite drug OK; General Motors gains with stock
|
10/9/2006 | BT | New River rated at buy by Merrill
|
9/25/2006 | BT | Merrill puts New River at buy
|
9/12/2006 | BT | New River meets enrollment in phase 3 study of NRP104 for ADHD
|
9/12/2006 | BT | Market Commentary: Oscient may bounce on expected FDA rejection; New River rises 6%; Adolor flat, Progenics lower
|
9/7/2006 | BT | Market Commentary: New River falls over 10%; Cell Genesys loses 5% after-hours; Ligand, King up; Sinovac up 7%
|
8/15/2006 | BT | New River reiterated at buy by Merrill
|
8/15/2006 | BT | Market Commentary: Acadia gains; Shire, Barr, New River up on settlement; Novavax rises; Vasogen off
|
8/10/2006 | BT | Merrill reiterates New River at buy
|
7/28/2006 | BT | New River reiterated at buy by Merrill
|
7/25/2006 | BT | New River to co-promote NRP104
|
7/25/2006 | BTCV | New River closes $135 million convertibles sale with partial exercise of greenshoe
|
7/20/2006 | BTCV | New Issue: New River prices $125 million seven-year convertibles within talk, at 3.5%, up 25%
|
7/20/2006 | BT | Market Commentary: Amgen weakens; Gilead off 3%; Alfacell falls 30%; Nektar up; Accentia lower; Connetics lifted
|
7/20/2006 | CV | Market Commentary: Intel, Ford, Barnes fall on earnings weakness; New River quiet on debut; Essex plans $130 million deal
|
7/19/2006 | BT | Market Commentary: Amgen up slightly ahead of earnings; Isis, NeoPharm, Genta up; Affymetrix off, Illumina up 29%
|
7/19/2006 | CV | Market Commentary: Yahoo! stumbles on product delay; airlines better on earnings; New River's poor borrow hampers deal
|
7/19/2006 | BTCV | New River prices $125 million convertibles to yield 3.5%, up 25%
|
7/18/2006 | BT | Market Commentary: Tercica up 12%, Insmed rises 9%; Neurocrine closes weaker; Pharma Product up; New River deal emerges
|
7/18/2006 | CV | Market Commentary: Avnet improves on Lehman recommendation; Sanmina-SCI unmoved by warning; New River plans deal
|
7/18/2006 | BTCV | New River to price $125 million seven-year convertibles, talked at 3.25%-3.75%, up 22.5%-27.5%
|
6/30/2006 | BT | New River files IND for thyroid hormone-replacement therapy
|
6/21/2006 | BT | New River reiterated at buy by Merrill
|
6/20/2006 | BT | New River says NRP104 unlikely to be abused intravenously
|
6/19/2006 | BT | New River: Studies show NRP104 less euphoric than other ADHD drugs
|
6/19/2006 | BT | Merrill reiterates New River at buy
|
5/25/2006 | BT | New River reiterated at buy by Merrill
|
5/25/2006 | BT | Market Commentary: Cubist explodes ahead of Cubicin vote; Encysive advances; Seattle Genetics, Progenics gain on pact
|
5/24/2006 | BT | Shire, New River present positive study results for ADHD drug NRP104
|
5/24/2006 | BT | New River says NRP104 reduces ADHD symptoms in children
|
5/23/2006 | BT | New River begins pivotal phase 3 trial of NRP104 for treatment of ADHD in adults
|
5/23/2006 | BT | New River reiterated at buy by Merrill
|
5/12/2006 | BT | Merrill keeps New River at buy
|
5/1/2006 | BT | Merrill puts New River at buy
|
4/11/2006 | BT | New River names John Thottathil chief scientific officer
|
3/24/2006 | BT | Merrill reiterates New River at buy
|
3/13/2006 | BT | New River keeps buy rating from Merrill
|
3/10/2006 | BT | New River reports $29.9 million net loss for fiscal year 2005
|
3/3/2006 | BT | New River reiterated at buy by Merrill
|
2/27/2006 | BT | New River reiterated at buy by Merrill
|
2/10/2006 | BT | Merrill reiterates New River at buy
|
2/10/2006 | BT | Market Commentary: Acorda shares close up 12%; Shire better, other ADHD names off on drug labeling; Pfizer slides
|
2/8/2006 | BT | Merrill keeps New River at buy
|
2/7/2006 | BT | New River presents study results for possible pain reliever, receives $50 million milestone
|
2/6/2006 | BT | Merrill reiterates New River at buy
|
1/27/2006 | BT | New River's application for ADHD drug accepted for FDA review
|
1/27/2006 | BT | Merrill reiterates New River at buy
|
1/20/2006 | BT | New River kept by Merrill at buy
|
1/17/2006 | BT | Merrill reiterates New River Pharma at buy
|
12/12/2005 | BT | New River still a buy, Merrill says
|
12/7/2005 | BT | New River, Shire announce New Drug Application for ADHD-drug NRP104
|
12/7/2005 | BT | Merrill reiterates New River at buy
|
12/6/2005 | BT | Market Commentary: Cephalon dips on acquisition; New River off; Ipsen prices IPO in France; Exelixis ends off highs
|
12/5/2005 | BT | Merrill Lynch: New River still a buy
|
11/16/2005 | BT | Merrill Lynch raises New River price target to $85
|
11/3/2005 | BT | Merrill reiterates New River at buy
|
10/20/2005 | BT | Merrill Lynch reiterates New River as buy
|
10/13/2005 | BT | New River kept at buy rating by Merrill
|
9/29/2005 | BT | Market Commentary: Genomic, Avalon sink after IPOs price at low end; Forest, Cypress dive; SkinMedica's IPO on deck
|
9/13/2005 | BT | New River price target upped by Merrill
|
9/6/2005 | BT | New River reiterated by Merrill Lynch at buy
|
9/6/2005 | BT | Market Commentary: Chiron rises on rejection of bid from Novartis; Barr, Teva gain; New River higher; Andrx falls
|
8/24/2005 | BT | Market Commentary: Shire rises on Adderall news; New River retraces gain; Barr declines; Genaera gains; Oscient Pharma off
|
8/18/2005 | BT | New River reiterated at buy: Merrill
|
8/16/2005 | BT | New River reiterated by Merrill at buy
|
7/18/2005 | BT | New River Pharma's executives' stock trading plans should boost liquidity without dilution
|
7/18/2005 | BT | New River Pharma reiterated by Merrill at buy
|
7/14/2005 | BT | New River Pharma initiated by Merrill at buy
|